ERT and Bioclinica Become Clario
ERT announced that following its early Q2 merger with Bioclinica, the combined company is renamed Clario. Clario is a technology company that generates clinical evidence by fusing scientific knowledge and global scale into the endpoint technology platform.
Only Clario can deliver Trial Anywhere, the ability to execute decentralized, hybrid and site-based clinical trials by deploying technology while maintaining the precision and reliability of evidence.
Since 1990, Clario has completed more than 19,000 clinical trials and contributed to 870 regulatory approvals. Between 2019 and 2020 alone, Clario supported 70% of all Federal and Drug Administration (FDA) approvals.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
